I think they will address Calcitonin revenues, because there was expectation of it being a decent revenue generator.
With respect to the company's fixed expenses, I think we need to recalibrate the burn rate as a result of the sublease to AVII which is either substantially or entirely out of the 3Q numbers.
Combine that with the prospect of more traffic through the labs that required the hiring of a traffic cop (June A.) and the phone bill should be less of a concern and the state of the science becomes the focus again.
